GenAI in clinical development must be governed, repeatable, and auditable. Bryan shares Thermo Fisher’s scaling approach - an isolated enterprise LLM, ring-fenced patient-impacting workflows, and a ruthless ROI path - applied across ~3,000 global clinical trials each year.
• Segmenting patient-impacting vs business tasks; apply stricter controls where harm possible exists.
• Operating isolated enterprise LLM with auditable prompts, retrieval, outputs, and lineage tracking.
• Prototyping small, fail fast; scale only with ROI and regulatory acceptance evidence.
A compliance-first blueprint you can defend to MHRA/FDA - controls, evaluation, documentation - and a funding cadence that prioritises value over novelty.
Check out the incredible speaker line-up to see who will be joining Bryan.
Download The Latest Agenda